Compare MORN & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MORN | BLCO |
|---|---|---|
| Founded | 1984 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.4B |
| IPO Year | 2004 | 2022 |
| Metric | MORN | BLCO |
|---|---|---|
| Price | $172.61 | $16.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $256.50 | $18.45 |
| AVG Volume (30 Days) | 339.9K | ★ 348.0K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | ★ 3.38 | N/A |
| EPS | ★ 2.73 | N/A |
| Revenue | $2,445,500,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $9.14 | $8.65 |
| Revenue Next Year | $7.23 | $5.59 |
| P/E Ratio | $61.38 | ★ N/A |
| Revenue Growth | ★ 7.49 | 6.47 |
| 52 Week Low | $141.49 | $13.09 |
| 52 Week High | $289.61 | $18.92 |
| Indicator | MORN | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 54.78 | 51.14 |
| Support Level | $161.01 | $15.36 |
| Resistance Level | $180.63 | $16.64 |
| Average True Range (ATR) | 6.00 | 0.46 |
| MACD | 0.69 | -0.08 |
| Stochastic Oscillator | 69.57 | 26.16 |
Morningstar Inc is a provider of independent investment insights to financial advisers, asset managers, and investors. It provides data and research insights on various investment offerings, including managed investment products, publicly listed companies, private capital markets, debt securities, and real-time market data. The company has five reportable segments: Morningstar Direct Platform, PitchBook, Morningstar Credit, Morningstar Wealth, and Morningstar Retirement. Maximum revenue is derived from the Morningstar Direct Platform, which provides investors with comprehensive data, research, insights, and investment analysis through product areas such as Morningstar Data, Morningstar Direct, and Morningstar Advisor Workstation. Geographically, it generates maximum revenue from the USA.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.